Craig-Hallum Maintains Buy on Exagen, Lowers Price Target to $10
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Craig-Hallum analyst John Wilkin maintains Exagen (NASDAQ:XGN) with a Buy and lowers the price target from $12 to $10.
Craig-Hallum analyst John Wilkin maintains Exagen (NASDAQ:XGN) with a Buy and lowers the price target from $12 to $10.